Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label intrathecal Neuro-Cells safety study in chronic traumatic spinal cord injury
NL-OMON46581Phase 1Withdrawn
- Sponsor
- Neuroplast
- Start
- Apr 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Neuro-Cells in acute spinal cord injury (SCI), sponsored by Neuroplast. Primary endpoints: Adverse events and serious adverse events, Physical assessment changes and 2 more. Planned start Apr 2018; status: withdrawn.
02
Drugs
Neuro-Cells
03
Conditions
acute spinal cord injury (SCI)
Beyond the preview
Go deeper on NL-OMON46581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46581.